Patents by Inventor Audrey Laroche-Clary

Audrey Laroche-Clary has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Increased dosage of efavirenz for the treatment of cancer
    Patent number: 9468646
    Abstract: The invention is based on the finding that an increased daily dose of Efavirenz should be used for the treatment of cancer compared to the daily dose used in the treatment of AIDS. The invention thus relates to the use of Efavirenz for preparing a medicament intended for the treatment of cancer, wherein Efavirenz is administered at a dose generating an Efavirenz plasma concentration in said patient superior to 3000 ng/ml. It further relates to the use of Efavirenz for preparing a medicament intended for the treatment of cancer, wherein Efavirenz is administered at a daily dose of at least 1800 mg, in particular between 1800 and 2200 mg. It also relates to the use of Efavirenz for preparing a medicament intended for the treatment of cancer, in which the daily dose of Efavirenz is optimized after administration of a preliminary daily dose and measure or Efavirenz plasma concentration.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: October 18, 2016
    Assignee: ALIENOR FARMA
    Inventors: Pier Vincenzo Piazza, Nadine Houede, Audrey Laroche-Clary
  • Increased Dosage of Efavirenz for the Treatment of Cancer
    Publication number: 20150366871
    Abstract: The invention is based on the finding that an increased daily dose of Efavirenz should be used for the treatment of cancer compared to the daily dose used in the treatment of AIDS. The invention thus relates to the use of Efavirenz for preparing a medicament intended for the treatment of cancer, wherein Efavirenz is administered at a dose generating an Efavirenz plasma concentration in said patient superior to 3000 ng/ml. It further relates to the use of Efavirenz for preparing a medicament intended for the treatment of cancer, wherein Efavirenz is administered at a daily dose of at least 1800 mg, in particular between 1800 and 2200 mg. It also relates to the use of Efavirenz for preparing a medicament intended for the treatment of cancer, in which the daily dose of Efavirenz is optimized after administration of a preliminary daily dose and measure or Efavirenz plasma concentration.
    Type: Application
    Filed: January 23, 2013
    Publication date: December 24, 2015
    Inventors: Pier Vincenzo Piazza, Nadine Houede, Audrey Laroche-Clary